Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1996 Jan;171(1):170-4; discussion 174-5.
doi: 10.1016/S0002-9610(99)80094-4.

Carcinoma of the periampullary region: who benefits from portal vein resection?

Affiliations
Clinical Trial

Carcinoma of the periampullary region: who benefits from portal vein resection?

J D Roder et al. Am J Surg. 1996 Jan.

Abstract

Background: The prognosis of patients with carcinoma of the periampullary region infiltrating the portal vein is dismal.

Patients and methods: We assessed the morbidity, mortality, and prognosis of pancreatoduodenectomy in 31 patients in whom a tangential excision (n = 9) or a segmental resection (n = 22) of the portal vein or superior mesenteric vein was performed in an attempt to achieve complete tumor removal.

Results: There was no postoperative mortality. Tumor infiltration of the resected vein could be documented histopathologically in 19 of the 31 (61.3%) patients. All patients with pancreatic or bile duct carcinoma (n = 29) died within 16 months of the resection (median survival 8 months). In contrast, 2 patients with cystadenocarcinoma and acinous cell carcinoma are alive with no evidence of recurrence at 23 and 54 months, respectively.

Conclusion: Portal vein resection does not prolong survival in patients undergoing partial pancreatoduodenectomy for carcinoma of the pancreas or distal bile duct. Only the occasional patient with a rare tumor at this region may benefit from this approach.

PubMed Disclaimer

Publication types

LinkOut - more resources